| Status: Excluded due to NICE appraisal | |
Product meets AWMSG exclusion criteria due to NICE appraisal TA1159: Lisocabtagene maraleucel for treating relapsed or refractory large B-cell lymphoma after 2 or more lines of systemic treatment |
|
Medicine details |
|
| Medicine name | lisocabtagene maraleucel (Breyanzi®) |
| Formulation | 1.1-70 × 10^6 cells/mL dispersion for infusion |
| Reference number | 3448 |
| Indication | Treatment of relapsed or refractory large B-cell lymphoma after 2 or more systemic treatments |
| Company | Bristol-Myers Squibb Pharmaceuticals Ltd |
| BNF chapter | Malignant disease & immunosuppression |
| Assessment type | N/A |
| Status | Excluded due to NICE appraisal |
| Date of issue | 01/05/2026 |
| NICE guidance | |